Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-up of the MURANO Phase III Study

Post-treatment MRD analysis of MURANO: fixed-duration venetoclax-rituximab produced high rates of undetectable MRD that were associated with longer survival. Level 2 (MRD analysis of an RCT).

J Clin OncolPubMed 30523712